Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LJPC La Jolla Pharmaceutical		$5.73	$3.07 ▼ $6.24	$155.11M	2.39	158,476 shs	66,708 shs
LOGC LogicBio Therapeutics	$7.72 +3.1%	$2.06	$0.26 ▼ $3.77	$202.88M	2.06	168,718 shs	274,731 shs
NVAX Novavax	$7.00	$6.88	$5.01 ▼ $17.81	$1.13B	2.69	6.15 million shs	2.59 million shs
SLDB Solid Biosciences	$6.39 +10.4%	$4.26	$2.41 ▼ $10.37	$495.29M	2.34	1.23 million shs	3.44 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LJPC La Jolla Pharmaceutical	0.00%	0.00%	0.00%	0.00%	0.00%
LOGC LogicBio Therapeutics	+4.03%	0.00%	-7.07%	+11.13%	+22.39%
NVAX Novavax	+0.57%	-1.41%	+7.86%	+16.67%	-55.84%
SLDB Solid Biosciences	+3.76%	+6.83%	+25.60%	+127.06%	-35.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	1.8876 of 5 stars	0.0	5.0	0.0	4.7	1.1	0.8	0.6
NVAX Novavax	4.3379 of 5 stars	3.1	1.0	0.0	4.7	1.6	0.8	3.1
SLDB Solid Biosciences	3.3171 of 5 stars	4.6	1.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LJPC La Jolla Pharmaceutical	0.00	N/A	N/A	N/A
LOGC LogicBio Therapeutics	0.00	N/A	N/A	N/A
NVAX Novavax	2.29	Hold	$17.00	142.86% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	136.31% Upside

Current Analyst Ratings Breakdown

Latest NVAX, SLDB, LOGC, and LJPC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LJPC La Jolla Pharmaceutical	$75.72M	0.00	N/A	7.95	($2.94) per share	0.00
LOGC LogicBio Therapeutics	$287M	0.71	N/A	N/A	$8.96 per share	0.86
NVAX Novavax	$682.16M	1.66	N/A	N/A	($3.89) per share	-1.80
SLDB Solid Biosciences	$8.09M	61.22	N/A	N/A	$3.43 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LJPC La Jolla Pharmaceutical	$19.66M	$0.12	51.84	0.00	N/A	8.54%	-5.46%	4.00%	N/A
LOGC LogicBio Therapeutics	-$317M	-$5.79	N/A	∞	N/A	-141.03%	-81.98%	-52.13%	N/A
NVAX Novavax	-$187.50M	$2.65	2.64	87.50	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest NVAX, SLDB, LOGC, and LJPC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NVAX Novavax	-$0.12	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/9/2025	Q1 2025	LOGC LogicBio Therapeutics	N/A	-$0.27	N/A	-$0.27	N/A	N/A
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LJPC La Jolla Pharmaceutical	N/A	4.02	3.52
LOGC LogicBio Therapeutics	N/A	31.60	31.60
NVAX Novavax	N/A	2.06	2.03
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LJPC La Jolla Pharmaceutical	97.06%
LOGC LogicBio Therapeutics	46.05%
NVAX Novavax	53.04%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
LJPC La Jolla Pharmaceutical	36.30%
LOGC LogicBio Therapeutics	8.10%
NVAX Novavax	1.00%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LJPC La Jolla Pharmaceutical	61	24.94 million	15.89 million	Optionable
LOGC LogicBio Therapeutics	62	26.28 million	24.16 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable

NVAX, SLDB, LOGC, and LJPC Headlines

Recent News About These Companies

Analysts Set Expectations for SLDB FY2027 Earnings

July 17 at 3:49 AM | americanbankingnews.com

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?

July 16 at 7:33 AM | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

July 16 at 2:48 AM | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15 at 6:18 PM | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10, 2025 | seekingalpha.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10, 2025 | investing.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10, 2025 | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9, 2025 | msn.com

SLDB - Solid Biosciences Inc Price vs Fair Value - Morningstar

July 8, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at Citigroup

June 27, 2025 | marketbeat.com

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, SLDB, LOGC, and LJPC Company Descriptions

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Novavax NASDAQ:NVAX

$7.00 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.98 -0.02 (-0.29%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Solid Biosciences NASDAQ:SLDB

$6.39 +0.60 (+10.36%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 +0.07 (+1.16%)

As of 07:55 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time